Order Article Reprints

Smith AL, Eiken AP, Skupa SA, Moore DY, Umeta LT, Smith LM, Lyden ER, D’Angelo CR, Kallam A, Vose JM, et al. A Novel Triple-Action Inhibitor Targeting B-Cell Receptor Signaling and BRD4 Demonstrates Preclinical Activity in Chronic Lymphocytic Leukemia. International Journal of Molecular Sciences. 2022; 23(12):6712. https://doi.org/10.3390/ijms23126712

Smith, Audrey L., Alexandria P. Eiken, Sydney A. Skupa, Dalia Y. Moore, Lelisse T. Umeta, Lynette M. Smith, Elizabeth R. Lyden, Christopher R. D’Angelo, Avyakta Kallam, Julie M. Vose, and et al. 2022. "A Novel Triple-Action Inhibitor Targeting B-Cell Receptor Signaling and BRD4 Demonstrates Preclinical Activity in Chronic Lymphocytic Leukemia" International Journal of Molecular Sciences 23, no. 12: 6712. https://doi.org/10.3390/ijms23126712

Smith, A. L., Eiken, A. P., Skupa, S. A., Moore, D. Y., Umeta, L. T., Smith, L. M., Lyden, E. R., D’Angelo, C. R., Kallam, A., Vose, J. M., Kutateladze, T. G., & El-Gamal, D. (2022). A Novel Triple-Action Inhibitor Targeting B-Cell Receptor Signaling and BRD4 Demonstrates Preclinical Activity in Chronic Lymphocytic Leukemia. International Journal of Molecular Sciences, 23(12), 6712. https://doi.org/10.3390/ijms23126712